Polyplus, which provides upstream solutions for biologic and cell and gene therapy production from research to commercial grade, introduced its transgene plasmid engineering services for viral vector manufacturing. The expansion of plasmid services can be used stand alone, or as a complement to PEIproR and FectoVIR-AAVR reagents and kits for next generation viral vector and gene therapy manufacturing.
Following the early 2022 acquisition of e-Zyvec, integration activities have focused on providing a deeper level of solutions support to customers, according to Mario Philips, CEO at Polyplus, who adds that using the proprietary e-Zyvec technology, plasmids are assembled de novo, from a library of DNA bricks, removing the use of standard backbones that contain undesired DNA sequences. Plasmids reportedly can be engineered in two weeks using the Polyplus online plasmid engineering tool. These engineered plasmids can then be chosen for the delivery of the gene of interests used in gene therapies.
“We are now one of few companies in the market that can provide a fully customizable plasmid engineering service,” says Philips. “This innovative and rapid plasmid engineering service will help the viral vector industry to optimize process economics for advanced therapy manufacturing and enable customers to achieve their ambitious time-to-market goals.”